Q&A with Josh Levine of MicroCap Investor; Winning Strategy for Stocks in Biotech, Cleantech, and Emerging Technologies

New York, NY, Point Roberts WA, February 7, 2011 � Investorideas.com, an investor research portal specializing in sector investing including cleantech and biotech, interviews Josh Levine of the MicroCap Investor newsletter to gain insight on his research methodology.

Interview:
Q: Investorideas.com
Josh, your newsletter is unique in that you cover microcap stocks, which most investors associate with day trading -- but you research the space to look for long term wins. Can you tell investors why you look within the microcap space for those opportunities?
A: Josh Levine, MicroCap Investor
I view microcap investing as a long-term process that entails holding stocks one, three, five years and longer. It is endlessly fascinating and rewarding to invest in small companies developing new technologies and innovations, but it does require lots of patience and discipline. Jumping in and out of stocks only creates short term capital gains -- a tax consequence we try to avoid.
Successful microcap investing, above all else, relies on fundamental analysis and not market timing or seasonal variations. As long as investors focus on the market's inefficiencies at this level -- and capitalize on them -- they'll do very well in the long run.
This point about inefficiencies is extremely important. The gaps between the market's perspective and the fundamental realities of a company are vastly wider in smaller stocks than larger ones -- and that's why I‘ve uncovered so many enticing opportunities.
Like the old song goes, "You say potato and I say po-tah-to, you say tomato and I say to-mah-to ..." Similarly, investors in the microsphere seldom agree on the inherent values of these fledgling companies and, more specifically, their potential earnings power several years out.
Of course, that's what makes for a market and that's why there are usually buyers and sellers at almost every price. As they say, one man's trash is another man's treasure. In microcap land, where there are thousands of penny stocks and solid fundamentals are at a premium, there is lots of trash to sift through. Fortunately, I've been around the block enough times to know which neighborhoods hold the real treasures.
Q: Investorideas.com
You have a focus on biotech, cleantech, and other emerging technologies. Can you tell us why those key areas?
A: Josh Levine, MicroCap Investor
Small firms are able to concentrate on high-value-added functions where cutting-edge knowledge and technology are paramount. As a result, the microcaps that execute deliver amazingly high-growth margins and profits -- and fantastic returns to their investors.
By participating in transformational changes in the highest-growth industries, any microcap that successfully navigates the path from R&D to commercialization and beyond will emerge a big winner. There are no better sectors to find these companies than in biotechnology and medical technologies, cleantech and renewable energy, and advanced IT and networking technologies.
The life sciences is a particularly rich group to explore for exciting microcap opportunities. One reason is that big pharma companies are expected to lose as much as $140 billion in annual sales by 2016, as some of their key product patents expire. These drug giants are desperate for new innovations to revitalize their pipelines and small biotechs are an excellent source.
A surprisingly large number of the best microcap prospects reside in the biopharma and biotech sectors. I have always sought out and discovered bio companies with certain valuable attributes. Indeed, compared to the vast majority of sub-$100-million-market-value firms, the biotechs in our portfolio have seasoned management, big-league experienced boards, sane capital structures, enough cash to operate for more than 12 months, and solid partnerships with big pharmas.
In the energy world, for example, the shift to electric transportation will have far-reaching impact on nearly every industry and sector, from energy producers and suppliers to electrical equipment manufacturers and utilities to developers of the smart grid and numerous other advanced IT and energy technologies. Many small companies are building pieces of the emerging infrastructure and smart grids.
It's notable that one of the big boys in global electric infrastructure equipment, ABB, Inc. recently made a $10 million investment in a tiny company that supplies EV charging systems. Mergers and acquisitions will be happening more frequently among companies developing technologies for the smart grid. What's more, the anticipated IPOs this year for cleantech rising stars like Silver Spring Networks and BrightSource Energy will attract new investors.
Electric networks are the largest, most complex systems around, and it will take massive investments in technology over the next couple of decades to get them into shape to meet soaring demand for ever more efficient and ubiquitous electric power. As a consequence, a multitude of opportunities exist for small, innovative firms to capture lucrative market niches.
Q: Investorideas.com
You have just added a new stock to your watch list I understand. Can you tell us the criteria you have in place when you add a new stock and what you typically look for?
A: Josh Levine, MicroCap Investor
First, I want to point out there are variations in my decision-making process between, for instance, a nanocap listed on the OTC Bulletin Board and an established microcap with a $250 million market cap that's profitable with an institutional following.
For the smallest microcaps, it's essential to spend time with management and look at everything with a magnifying glass. For more seasoned companies, there is already a track record as well as more information available, which makes the due diligence process less of a maze.
Obviously, fundamental stock analysis is central, but I've learned that investing in small advanced-tech firms is as much art as science. It comes down to certain basics that apply across the board, and they are:

• People - starting with the founders and top management, nothing counts more than the quality, experience, track record, and credibility of those running the company.
• Technology - technologies need to perform well but they also must represent a transformational shift or add significant value by improving current products or systems.
• Markets - technologies must address a sizable market, or it's simply not worth the effort. Also, it's essential to monitor market trends and being clued in to what industry leaders are doing. As senior analyst for ChangeWave Research, I am able to track the pace of change across many industries.
• Intangibles - this covers everything under the intellectual property umbrella, from patents to trade secrets, including everything inside the heads of employees. There's nothing tougher to quantify, but it's vital to get as much understanding as you can about these assets.
• Capital Structure - this reveals a whole lot about a company's history and the ability of executives to manage growth and build for the future. Problems in the capital structure often cripple microcaps, so investors need to be very critical in their analysis.

Q: Investorideas.com
I remember hearing old time investors talking about making their big wins in the market by finding the next big thing and holding on for years. In the past few years that mentality has been dismantled by what transpired in 2008. Do you still see that kind of opportunity in the market - and what kind of wins are you seeing in your portfolio?
A: Josh Levine, MicroCap Investor
Yes, the opportunities for returns of 200%, 500%, 1,000% and higher continue to be out there. But to earn the truly life-altering profits, you need to be fully invested in the best microcap stocks prior to any major bull cycle. A big portion of gains are often made in the early phase of a bull market for microcaps, so you've got to be positioned early. Otherwise, by the time the trend takes shape, it's usually too late to build the kind of low-cost positions that ultimately deliver those ten-bagger profits.
Today I believe we're in the early stages of a microcap bull market, but it's difficult to predict the exact timing. Still, ever since the end of 2008 - even before the general market bottomed - the stocks in the MicroCap Investor portfolio have been trending higher.
We ended 2010 on a high note by capturing a 138% profit by selling one-half of our position in a company that's leading the charge, so to speak, in energy solutions for transportation.
Another microcap in our portfolio, a developer of a new class of cancer therapeutics, is up 240% since I first recommended it to subscribers. When I added this stock to our portfolio it was within pennies of its six-year low. The value of this biotech, which has a long-standing partnership with a leading biopharma and a healthy cash hoard, lies in the ability of its drugs to be used in combination therapies and its excellent prospects for attracting licensees. While its gains so far have been good, this stock could soar five to ten times its current price depending on the success of clinical trials for its various drugs.
In general, our biotech positions are looking very, very good. In less than six months, we're up 43% with a stem cell developer which already has two revenue-generating businesses. And a number of others have been regularly hitting new milestones, which eventually will be translated into much higher market valuations.
While all of the stocks in our portfolio are positioned for tremendous upside ahead, the most consistent performers have been what I call the “Mature Microcaps.” For instance, within this group we've got a gain of 109% with a supplier of advanced equipment for large-scale solar projects, and we're up 76% with a designer of 3G/4G wireless chips.
Finally, one of my favorite microcaps today is a company which has developed and is selling advanced mobile services to multi-billion dollar markets worldwide in dire need of its cost-effective and efficient solutions. We've already got a 120% gain, but I believe this one has all the characteristics of rapidly becoming one of the great microcap winners of the decade.
The recent activity in our micros, nice as it's been, hardly measures up to the bonanzas of past microcap bull runs. A big reason is that this bull market lacks the full participation of the public which has remained enormously risk-adverse after the blow-ups, busts and downturns of the past decade.
Depending on the breadth and length of this upturn, individual investors will increasingly come back into the game, and eventually in large numbers. By then, however, the biggest profits will have been registered by those investors positioned far ahead of the herd.
Josh Levine's MicroCap Investorhttp://www.levinesmicrocapinvestor.com
Levine's MicroCap Investor delves deep into the world of small stocks to identify big winners, targeting innovative companies on the path of the new and revolutionary.
About Josh Levine
Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks. He excels at assessing management teams and evaluating new innovations and their impact on corporate valuations.
More on Levine's bio: http://www.levinesmicrocapinvestor.com/aboutus/
To learn more about this and the other outstanding investment opportunities in the MicroCap Investor portfolio, subscribe now.
http://www.levinesmicrocapinvestor.com/subscriptions/order/
InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com team operates this web site and manages the administration and marketing for MicroCap Investor.
InvestorIdeas.com is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Levine's Microcap Investor
Disclaimer and disclosure for Levine's Microcap :
http://www.levinesmicrocapinvestor.com/disclosure/
Disclaimer and disclosure for Investorideas.com
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. http://www.investorideas.com/About/Disclaimer.asp
Contact us
admin@levinesmicrocapinvestor.com
800 665 0411

Biotech/Pharma Profile Update for BioSante Pharmaceuticals, Inc.

Key Highlight: BioSante Pharmaceuticals is Only Company in World In Phase III Clinical Development for Treatment of Female Sexual Dysfunction

Point Roberts, WA, LINCOLNSHIRE, Ill - February 3, 2011 Investorideas.com, a leader in sector research, updates the company profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.

Recent News:
"BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting"
LINCOLNSHIRE, Ill. - February 3, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Read the full news release, click here .
Company Overview:
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. www.biosantepharma.com
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Read the full BPAX Investor Presentation at: http://www.investorideas.com/CO/BPAX/news/2011/BPAX-Presentation-012111.pdf
Financial Highlights

• At December 31, 2010, BioSante had approximately $39M in cash
• Monthly burn rate of approximately $3.5M - $4.0M

Trading Data

• NASDAQ: BPAX
• Recent Price (2/2/11): $1.93
• Market Cap: $150M
• Average Daily Volume: 1.1M
• Common Shares Outstanding: 81.4M
• 52-Week Range: $1.29-$2.50
• Fiscal Year Ends: December 31

Investment Highlights

• Financial resources to continue corporate strategy
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Focused growth strategy
• Management's proven ability to gain FDA approval, implement plans and increase stockholder value

LibiGel Facts
Full LibiGel Brochure at: http://www.investorideas.com/CO/BPAX/news/2011/LibiGel-Brochure-Jan2011.pdf
LibiGel®* Treatment of Women with
Hypoactive Sexual Desire Disorder (HSDD)
LibiGel® is a gel formulation of testosterone in development that is quickly absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
Regulatory Status
The LibiGel clinical development program, in consultation and agreement with the FDA, has been designed to show that LibiGel can safely improve women's sexual desire and the frequency of satisfying sexual events and decrease personal distress associated with low sexual desire in women with HSDD. BioSante is conducting three Phase III LibiGel clinical studies and BioSante's objective is to submit a new drug application (NDA) to the FDA in 2011 for a potential approval in 2012.
Progress and Plans in Phase III:
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, double blind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA's position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel.
In addition to the two Phase III safety and efficacy trials covered by the SPA, BioSante is conducting one Phase III cardiovascular and breast cancer safety study of LibiGel, which also is underway. The safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study of between 2,750 and
4,000 women exposed to LibiGel or placebo. BioSante will follow the women enrolled in the safety study for a total of 5 years. However, after an average of 12 months' exposure BioSante intends to submit a LibiGel NDA for review and potential approval by FDA.
The LibiGel safety study is tracking a composite of cardiovascular events including cardiovascular death, myocardial infarction and stroke in women with FSD who are 50 years of age or older and have at least two cardiovascular risk factors such as hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of cardiovascular events. The incidence of breast cancer also will be tracked throughout the study.
BioSante has reported that in the first 2,750 women enrolled comprising approximately 2,700 women-years of exposure, there have been only 14 adjudicated cardiovascular events even though the safety study is enrolling women with a higher risk of cardiovascular events. To date, over 2,750 women have been enrolled.
BioSante's obective is to submit the LibiGel NDA in 2011 for a potential FDA approval in 2012.
Contact BioSante Pharmaceuticals
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
To the extent any statements made in this news release deal with information that is not hist orical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Disclaimer: This news release is part of a monthly information distribution program for BioSante (BPAX) (one thousand dollars per month). Investorideas.com is a third party publisher of news and research .All information on featured companies is prepared by the company or taken from public filings and news releases. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech/pharma, mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Visit our Biotech investor portal : www.biotechindustrystocks.com
Research more biotech stocks at the Biotech stocks Directory
Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante Pharmaceuticals Inc.
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411: cvanzant@investorideas.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting

LINCOLNSHIRE, Ill. - February 2, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.

Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stocks News; UV Flu Technologies to Become an Official Equipment Supplier to Hockey Canada

CENTERVILLE, MA � February 1, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's athletic distributor, New England Sports Sales ("NESSI"), a national distributor of hockey and related athletic equipment to college and professional hockey teams across the US and Canada, has been notified that they will be facilitating the shipment of ViraTech UV-400 air purifiers to the Hockey Canada practice and training facility in Calgary.

The WinSport Canada facility operates under the scope of Hockey Canada, the national body regulating the sport across Canada. Located in Calgary's Canada Olympic Park, the 500,000-square-foot structure currently includes three North American-size ice rinks designed for hockey, sledge hockey as well as figure skaters. The facility has already been dubbed a calling card for Calgary in continuing to attract world-class athletes to the city.
With this shipment, scheduled for delivery upon completion of the facility, UV Flu will become an official supplier to Hockey Canada, and will continue to build brand awareness within the sport by directly introducing the product to the athletes who will benefit the most by its use. Hockey Canada will be an excellent addition to the growing list of teams and facilities utilizing the product including the Boston Bruins, Pittsburgh Penguins, and several notable college organizations.
"We believe we have not even scratched the surface for the potential demand of this product in the professional and college athletic marketplace," commented Charles Gulteri, President of NESSI. "Hockey and basketball are major sports where every player is critical to the team and the constant travel and changing weather conditions during cold and flu season create fertile conditions for the spread of illness. The UV-400 will prevent the spread of many of these airborne illnesses for an incredibly low price and we believe teams cannot afford to be without them in their team areas. We plan on talking with the NHL, as well as college teams, to further educate them on the importance of this product," said Mr. Gulteri.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Completes Acquisition of RxAir Industries

CENTERVILLE, MA � January 31, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has completed an agreement securing the acquisition of RxAir Industries, LLC, ("RxAir") headquartered in Dallas, Texas.

RxAir (www.rxair.com) is a well-known and highly regarded manufacturer of high quality air purification equipment designed for applications within the medical and hospitality marketplace, and also includes products geared for specialized industrial applications, such as emergency preparedness.
The agreement includes a patented, trademarked product line, with national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The Company has been in business for 15 years, and existing sales include an installed base of several thousand units in over 1000 unique facilities nationwide, including over 400 hospitals. The Company's two main products, the RX3000, which is the Company's best seller, provides air purification coverage in spaces up to 2000 sq. ft, while the RX4500, also known as the "Smoke Handler," is the preferred choice of hospitality establishments nationwide. The unit protects spaces of up to 5000 sq. feet, and can be connected to existing ductwork. Both units can remove more than 99.97% of airborne contaminants and pathogens greater than 0.3 micrometers in size and are designed with exterior cabinetry able to match any d�cor. They combine multiple filter configurations, including HEPA, with germicidal UV lamps, making one of the most effective air purification systems in the world today.
"This acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a U.S. manufacturing base to aid our efforts in the pursuit of medical, hotel, casino, government and DoD contract opportunities, including military and government facilities," said Mr. John Lennon, President of UV Flu Technologies. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital and hospitality marketplace. The larger models and coverage that the RxAir units add to our product line open up a whole new marketplace for us. Larger public spaces like school cafeterias, gaming areas, restaurants, gymnasiums, and construction sites are now just some of the many potential new targets for our products. We believe the synergies will be extraordinary and hope to significantly increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for increased traction across the entire segment."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Biotech/Pharma Stock News; BioSante (NASDAQ: BPAX) Announces FDA Orphan Drug Designation for its Melanoma Cancer Vaccine

LINCOLNSHIRE, Ill. - January 25, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

The orphan drug designation for the Melanoma Cancer Vaccine is BioSante's fourth orphan drug designation for BioSante's portfolio of cancer vaccines; the company also has received orphan drug designations for its vaccines to treat pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia.
"We continue to develop our vaccine portfolio in cooperation with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center," said Stephen M. Simes, president and chief executive officer of BioSante. "Clinical trials of our cancer vaccines are being conducted to treat leukemia, breast cancer, and pancreatic cancer, among other cancer types. In addition, we expect to report on pancreatic cancer study results in the near future."
It is estimated that, in the U.S., over 68,000 people were diagnosed with and 8,700 died of melanoma in 2010. While it is more common in Caucasian populations living in sunny climates, it can be found in almost any groups, including those who use tanning salons. Melanoma is the most serious form of skin cancer, however, if it is recognized and treated early, it is nearly 100 percent curable. But if it is not, the cancer can advance and spread to other parts of the body, where it becomes difficult to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Signs First Distributor Exclusive to Personal Esthetics Sector

CENTERVILLE, MA � January 24, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the Company's flagship product, the ViraTech UV-400 indoor air purifier, is now being distributed through the Perfect Touch Beauty Network ("Perfect Touch") targeting the growing need for improved air quality at beauty salons across the country.

The driving force behind Perfect Touch is its industry renowned principal Debi Nemeth, a respected innovator, distributor and trainer headquartered in Colorado, who works with one of the top nail salon supply companies in the country, training and supplying over 200 nail technicians annually in Colorado, and from surrounding states. The nail salon supply company distributes products, trains estheticians and management, plus licenses hundreds of branded locations throughout the Country and around the globe. Ms. Nemeth trains new and current nail salon owners, particularly with respect to new products and technologies, while also providing an esthetics training curriculum for three colleges within Colorado.
"I not only train and distribute nail products, I'm an owner of a salon, which gives me the ability to test all of the products I distribute, as we only use the best," said Ms. Nemeth. "As a salon owner as well as an educator it was impressive to experience such immediate results. When we brought the ViraTech UV-400 into our salon, our clients couldn't believe the difference! They actually noticed there was no smell in the salon whatsoever, other than a fresh, outdoor quality. Our customers really appreciate that we value their health and my staff has not had one sick day since we brought in the device. I recommend it as an essential piece of equipment for any salon owner, as it pays for itself within weeks by bringing in more business, while also reducing absenteeism."
"Salons all over the Country are already starting to experience regulations on hygiene, and air quality inside their businesses," said John Lennon, President of UV Flu Technologies. "Product trainers and distributors alike that have tried our product truly think it is a game changer, as it protects employees, as well as customers, from toxic fumes and noxious odors, while also keeping them healthy from the spread of airborne bacteria. The units are increasing salon business, while dramatically decreasing the number of complaints from neighbors, particularly with respect to operations located within malls. We think Ms. Nemeth will be incredibly helpful in educating salon owners that this is a product that really works."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp